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Abstract
Pure, soluble and functional proteins are of high demand in modern biotechnology. Natural protein
sources rarely meet the requirements for quantity, ease of isolation or price and hence
recombinant technology is often the method of choice. Recombinant cell factories are constantly
employed for the production of protein preparations bound for downstream purification and
processing. Eschericia coli is a frequently used host, since it facilitates protein expression by its
relative simplicity, its inexpensive and fast high density cultivation, the well known genetics and the
large number of compatible molecular tools available. In spite of all these qualities, expression of
recombinant proteins with E. coli as the host often results in insoluble and/or nonfunctional
proteins. Here we review new approaches to overcome these obstacles by strategies that focus on
either controlled expression of target protein in an unmodified form or by applying modifications
using expressivity and solubility tags.
Introduction
Microorganisms like the enterobacterium Escherichia coli
are outstanding factories for recombinant expression of
proteins. An expression system for the production of
recombinant proteins in E. coli usually involves a combi-
nation of a plasmid and a strain of E. coli [1]. The main
purpose of recombinant protein expression is often to
obtain a high degree of accumulation of soluble product
in the bacterial cell. This strategy is not always accepted by
the metabolic system of the host and in some situations a
cellular stress response is encountered. Another response
encountered in recombinant systems is the accumulation
of target proteins into insoluble aggregates known as
inclusion bodies. These aggregated proteins are in general
misfolded and thus biologically inactive [2].
Under normal cellular conditions a subset of cytoplasmic
proteins are able to fold spontaneously [3] while aggrega-
tion prone proteins require the existence of a number of
molecular chaperones that interact reversibly with nascent
polypeptide chains to prevent aggregation during the
folding process [4]. Aggregation of recombinant proteins
overexpressed in bacterial cells could therefore result
either from accumulation of high concentrations of fold-
ing intermediates or from inefficient processing by molec-
ular chaperones. No universal approach has been
established for the efficient folding of aggregation prone
recombinant proteins [1].
The literature describes a number of methods for the redi-
rection of proteins from inclusion bodies into the soluble
cytoplasmic fraction (Figure 1). Overall they can be
divided into procedures where protein is refolded from
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inclusion bodies [5] and procedures where the expression
strategy is modified to obtain soluble expression. In this
review we focus on methods developed for soluble expres-
sion in the E. coli cytoplasm. Refolding from inclusion
bodies is in many cases considered undesireable, but is
however sometimes the method of choice. The major
obstacles are the poor recovery yields, the requirement for
optimization of refolding conditions for each target pro-
tein and the possibility that the resolubilization proce-
dures could affect the integrity of refolded proteins. In
addition, the purification of highly expressed soluble pro-
tein is less expensive and time consuming than refolding
and purification from inclusion bodies. Maximizing the
production of recombinant proteins in a soluble form is
therefore an attractive alternative to in vitro refolding pro-
cedures. The methods used to mediate soluble expression
can be divided into procedures where target modification
is avoided and procedures where the target sequence is
engineered (Figure 1).
Strategies where target modification is avoided
Some proteins directly influence the cellular metabolism
of the host by their catalytic properties, but in general
expression of recombinant proteins induces a "metabolic
burden". The metabolic burden is defined as the amount
of resources (raw material and energy), which are with-
drawn from the host metabolism for maintenance and
expression of the foreign DNA [6]. The formation of inclu-
sion bodies occurs as a response to the accumulation of
denatured protein. The metabolic burden and inclusion
body formation are not directly linked but are both
among the main factors to determine the ability of cells to
produce soluble recombinant protein. Since the accumu-
lation of denatured protein and the metabolic burden can
Downstream applications employed to obtain soluble proteins from recombinant E. coli Figure 1
Downstream applications employed to obtain soluble proteins from recombinant E. coli. As a common trait the in vivo strate-
gies aims at lowering the metabolic burden associated with recombinant expression. Some of the mentioned strategies have 
therefore merely indirect influence on folding such as the use of tRNA complementation plasmids and stabilization of mRNA 
(see text and ref [1] for details).
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be controlled by a number of environmental factors, we
are partially able to control the formation of soluble pro-
tein in vivo.
Protein expression at reduced temperatures
A well known technique to limit the in vivo aggregation of
recombinant proteins consists of cultivation at reduced
temperatures [7]. This strategy has proven effective in
improving the solubility of a number of difficult proteins
including human interferon α-2, subtilisin E, ricin A
chain, bacterial luciferase, Fab fragments, β-lactamase,
rice lipoxygenase L-2, soybean lypoxygenase L-1, kanamy-
cin nuclotidyltransferase and rabbit muscle glycogen
phosphorylase (see [8] and references cited therein).
The aggregation reaction is in general favored at higher
temperatures due to the strong temperature dependence
of hydrophobic interactions that determine the aggrega-
tion reaction [9]. A direct consequence of temperature
reduction is the partial elimination of heat shock pro-
teases that are induced under overexpression conditions
[10]. Furthermore, the activity and expression of a
number of E. coli chaperones are increased at tempera-
tures around 30°C [11,12]. The increased stability and
potential for correct folding at low temperatures are par-
tially explained by these factors.
However, a sudden decrease in cultivation temperature
inhibits replication, transcription and translation [13].
Traditional promoters used in vectors for recombinant
protein expression are also strongly affected in terms of
efficiency [14]. A similar transcriptional effect is achieved
when a moderately strong or weak promoter is used or
when a strong promoter is partially induced. Low induc-
tion levels have been found to result in higher amounts of
soluble protein [15]. This is a result of the reduction in cel-
lular protein concentration which favors folding. How-
ever, bacterial growth is decreased, thus resulting in a
decreased amount of biomass.
Different strategies aimed at optimizing the expression of
recombinant proteins at low temperature are as follows.
A system based on the cspA promoter was developed for
the expression of proteins at low temperature [16]. The
cspA promoter is highly induced at low temperature and is
well repressed at and above 37°C. A sequence encoding
the TolAI-β-lactamase fusion protein which is toxic to E.
coli and rapidly degraded at 37°C was placed under the
control of the cspA promoter. Temperature downshift to
15 or 23°C abolished degradation of the fusion protein
and the toxic phenotype associated with expression at
37°C was suppressed. It was suggested that this system is
a valuable tool for the production of proteins containing
membrane-spanning domains or otherwise unstable gene
products in E. coli.
A principle that allows for protein expression and folding
at 4°C was presented recently [17]. This principle is based
on co-expression of the target protein with chaperones
from a psychrophilic bacterium. The two chaperones
(Cpn60 and Cpn10 from Oleispira antarctica RB8T) allow
E. coli to grow at high rates at 4°C [12]. An esterase from
O. antarctica RB8T  was co-expressed with Cpn60 and
Cpn10 in E. coli at 4°C. This procedure increased the spe-
cific activity of the purified esterase 180 fold as compared
to enzyme prepared from cultivations at 37°C. It was con-
cluded that the low temperature was beneficial to folding
and the system was suggested as a tool for expression and
correct folding of recombinant proteins in the cytoplasm
of E. coli.
E. coli strains used to improve soluble expression
Numerous specialized host strains have been developed
to overcome the metabolic burden related to high level
protein expression.
Two E. coli mutant strains have contributed significantly
to the soluble expression of difficult recombinant pro-
teins. C41(DE3) and C43(DE3) are mutants that allow
over-expression of some globular and membrane proteins
unable to be expressed at high-levels in the parent strain
BL21(DE3) [18]. Expression of the F1Fo ATP synthase sub-
unit b membrane protein in these strains, in particular
C43(DE3), is accompanied by the proliferation of intrac-
ellular membranes and inclusion bodies are absent [19].
These strains are now commercialized by Avidis http://
www.avidis.fr and a high number of reports on their use
in expression of difficult proteins have been published
[20-23]. A recent work reports that the stability of plas-
mids encoding toxic proteins is increased in C41(DE3)
and especially in C43(DE3) [24].
Cysteines in the E. coli cytoplasm are actively kept reduced
by pathways involving thioredoxin reductase and glutare-
doxin. The disulfide bond dependent folding of heterolo-
gous proteins is improved in the Origami strains from
Novagen. Disruption of the trxB and gor genes encoding
the two reductases, allow the formation of disulfide
bonds in the E. coli cytoplasm. The trxB (Novagen AD494)
and trxB/gor (Novagen Origami) negative strains of E. coli
have been selected in several expression situations [25-
27]. Folding and disulfide bond formation in the target
protein, is enhanced by fusion to thioredoxin in strains
lacking thioredoxin reductase (trxB) [28]. Overexpression
of the periplasmic foldase DsbC in the cytoplasm stimu-
lates disulfide bond formation further [27].Microbial Cell Factories 2005, 4:1 http://www.microbialcellfactories.com/content/4/1/1
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Modification of cultivation strategies to obtain soluble 
protein
The simplest way to produce a recombinant protein is by
batch cultivation. Here all nutrients required for growth
are supplied from the beginning and there is a limited
control of the growth during the process. This limitation
often leads to changes in the growth medium such as
changes in pH and concentration of dissolved oxygen as
well as substrate depletion. Furthermore inhibitory prod-
ucts of various metabolic pathways accumulate. Cell den-
sities and production levels are only moderate in batch
cultivations.
In fed batch cultivations, the concentration of energy
sources can be adjusted according to the rate of consump-
tion. Several other factors can also be regulated in order to
obtain the maximal production level in terms of target
protein per biomass. The formation of inclusion bodies
can be followed in fed batch cultivations by monitoring
changes in intrinsic light scattering by flow cytometry
[29]. This allows for real time optimization of growth con-
ditions as soon as inclusion bodies are detected even at
low levels and inclusion body formation can potentially
be avoided [30].
Folding of some proteins require the existence of a specific
cofactor. Addition of such cofactors or binding partners to
the cultivation media may increase the yield of soluble
protein dramatically. This was demonstrated for a recom-
binant mutant of hemoglobin for which the accumula-
tion of soluble product was improved when heme was in
excess [31]. Similarly, a 50% increase in solubility was
observed for gloshedobin when E. coli recombinants were
cultivated in the presence of 0.1 mM Mg2+ [32]. An impor-
tant factor in soluble expression of recombinant proteins
is media composition and optimization. Although this is
attained mostly by trial and error, it nevertheless may be
beneficial.
Molecular chaperones drive folding of recombinant 
proteins
A possible strategy for the prevention of inclusion body
formation is the co-overexpression of molecular chaper-
ones. This strategy is attractive but there is no guarantee
that chaperones improve recombinant protein solubility.
E. coli encode chaperones, some of which drive folding
attempts, whereas others prevent protein aggregation
[4,11,33]. As soon as newly synthesized proteins leave the
exit tunnel of the E. coli ribosome they associate with the
trigger factor chaperone [34]. Exposed hydrophobic
patches on newly synthesized proteins are protected by
association with trigger factor from unintended inter- or
intramolecular interactions thus preventing premature
folding. Proteins can start or continue their folding into
the native state after release from trigger factor. Proteins
trapped in non-native and aggregation prone conforma-
tions, are substrates for DnaK and GroEL. DnaK (Hsp70
chaperone family) prevents the formation of inclusion
bodies by reducing aggregation and promoting proteoly-
sis of misfolded proteins [11]. A bi-chaperone system
involving DnaK and ClpB (Hsp100 chaperone family)
mediates the solubilization or disaggregation of proteins
[35]. GroEL (Hsp60 chaperone family) operates the pro-
tein transit between soluble and insoluble protein frac-
tions and participates positively in disaggregation and
inclusion body formation. Small heat shock proteins lbpA
and lbpB protect heat denatured proteins from irreversi-
ble aggregation and have been found associated with
inclusion bodies [36,37].
Simultaneous over-expression of chaperone encoding
genes and recombinant target proteins proved effective in
several instances. Co-overexpression of trigger factor in
recombinants prevented the aggregation of mouse
endostatin, human oxygen-regulated protein ORP150,
human lysozyme and guinea pig liver transglutaminase
[38,39]. Soluble expression was further stimulated by the
co-overexpression of the GroEL-GroES and DnaK-DnaJ-
GrpE chaperone systems along with trigger factor [39].
The chaperone systems are cooperative and the most favo-
rable strategies involve co-expression of combinations of
chaperones belonging to the GroEL, DnaK, ClpB and
ribosome associated trigger factor families of chaperones
[40-42].
Interaction partners and protein folding
Protein insolubility in the E. coli cytoplasm is partially
related to the distribution of hydrophobic residues on the
surface of the protein. The soluble expression of subunits
of hetero multimeric proteins therefore sometimes suffers
from inclusion body formation in the absence of an
appropriate binding partner.
Soluble expression in E. coli of the bacteriophage T4 gene
23 product (major capsid protein) required the co-expres-
sion of gene product 31 (phage co-chaperonin gp31) [43].
Expression of the correct interaction partner enabled gp23
to fold correctly and form long regular structures in the
cytoplasm of E. coli.
Another study reports the purification of a heterodimeric
complex by expression of each subunit (pheromaxein A
and C) as a fusion to thioredoxin [44]. Each subunit
remained soluble in solution, when thioredoxin was pro-
teolytically removed, only in the presence of the other.
Conclusively, interaction partners potentially favour in
vivo  solubility of target proteins. New systems for co-
expression of multiple proteins involved in complex
structures enable such strategies [1].Microbial Cell Factories 2005, 4:1 http://www.microbialcellfactories.com/content/4/1/1
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Strategies involving engineered target protein
Target proteins are not always expressed in a soluble form
by the strategies described above. The last part of this
review discusses how misfolded proteins can be
engineered or pushed to evolve and selected to gain solu-
ble expression.
Fusion protein technology
The use of affinity tags in recombinant protein purifica-
tion has a long tradition. Not only have they been
exploited for the development of generic purification
strategies. Affinity tags have been observed to improve
protein yield, to prevent proteolysis and to increase solu-
bility in vivo [1,45].
Among the most potent solubility enhancing proteins
characterized to date are the E. coli maltose binding pro-
tein (MBP) and the E. coli N-utilizing substance A (NusA).
MBP (40 kDa) and NusA (54.8 kDa) act as solubility
enhancing partners and are especially suited for the
expression of proteins prone to form inclusion bodies.
Although many proteins are highly soluble, they are not
all effective as solubility enhancers. E. coli MBP proved to
be a much more effective solubility partner than the
highly soluble GST and thioredoxin proteins in a compar-
ison of solubility enhancing properties [46]. Solubility
enhancement is a common trait of maltodextrin-binding
proteins (MBPs) from a number of organisms and some
of them are even more effective than E. coli MBP [47]. A
precise mechanism for the solubility enhancement of
MBP has not been found. However, MBP might act as a
chaperone by interactions through a solvent exposed "hot
spot" on its surface which stabilizes the otherwise insolu-
ble passenger protein [48,49]. The ability of MBP to pro-
mote the solubility of fusion partners can be improved by
addition of supplemental tags. Different configurations
for MBP fusion proteins have been suggested for high-
throughput protein expression and purification [50].
Wilkinson and Harrison proposed a model for the theo-
retical calculation of solubility percentages of recom-
binant proteins expressed in the E. coli cytoplasm [51]. A
webserver for the calculation of this index is found at
http://www.biotech.ou.edu. The Wilkinson-Harrison
model along with experimental data identified NusA as a
highly favorable solubility partner [52]. The major advan-
tage of NusA, in addition to the good solubility character-
istics, is its high expressivity. Both MBP and NusA have
been used for the solubilization of highly insoluble ScFv
antibodies in the cytoplasm of E. coli [48,53]. Numerous
examples of MBP and NusA as functional solubility
enhancers are found in the literature [54-57].
Natural molecular chaperones that have been used as sol-
ubility enhancers include prolyl cis trans isomerases (PPI-
ases) [58], thioredoxin [59] and dsbA [60].
Fusion partners such as MBP and NusA are relatively large
proteins. We recently suggested the use of a highly soluble
N-terminal fragment of translation initiation factor IF2
(17.4 kDa) as a solubility partner [61]. The use of a small
partner reduces the amount of energy required to obtain a
certain number of molecules, diminishes steric hindrance
and simplify downstream applications such as NMR.
Another relatively small protein, barnase was suggested to
exert chaperone like functions both in vivo and in vitro
when fused to the C-terminus of the light chain variable
domain of an IgG [62].
In a recent study it was shown that a 17 residue C-terminal
extension of Pfg27 resulted in several fold enhancement
of soluble expression [63]. Several studies have shown
that the nature of terminal residues in proteins can play a
role in recognition and subsequent action by proteases
[64,65]. The terminal extension of proteins might there-
fore indirectly protect them from the denaturaturation/
misfolding associated to partial proteolytic degradation. It
has also been suggested that large net charges of peptide
extensions increases electrostatic repulsion between nas-
cent polypeptides and therefore enhances their correct
folding [66].
Screening strategies have been employed to select for favo-
rable fusion partners in a high throughput manner. In
such a system more than 80% of the proteins tested
showed high levels of expression of soluble products with
at least one of eight fusion partners including NusA,
intein, thioredoxin, His-tag, MBP, calmodulin binding
protein and glutathione-S-transferase [67]. These results
were supported by another similar study [68].
Screening for and selection of soluble variants
Structural and functional genomics and proteomics are
important elements in the evaluation of gene function.
The expression and purification of properly folded pro-
teins in a high throughput manner are key elements in
these studies. A number of different approaches to the
high throughput screening of soluble expression products
have been described recently.
The intrinsic folding yield, stability and solubility of target
proteins can be improved by engineering the target pro-
tein. When structural information is available, the solubil-
ity of the expressed protein has been improved by rational
site directed mutagenesis [69]. A more general approach is
to find more soluble variants by directed evolution.
Libraries generated in this context include random point
mutants, deletions and fragments [70]. The generatedMicrobial Cell Factories 2005, 4:1 http://www.microbialcellfactories.com/content/4/1/1
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mutants are screened for solubility either by the function
of the protein of interest or by more general screens. A
screen based on biological activity implies that a new
assay has to be developed for every new protein studied.
Moreover, in many cases the protein or protein domain
studied does not display any known activity at all. The
general screens include fusion reporter methods, stress
reporter methods and direct methods and are therefore
usually preferred for high-throughput approaches.
Fluorescence of E. coli cells expressing target genes fused to
the GFP-gene is related to the solubility of the target gene
expressed alone [71]. Hence, protein folding in E. coli can
be improved by directed evolution approaches for a cer-
tain target protein by screening for fluorescing mutants.
This approach evolved three insoluble proteins including
Pyrobaculum aerophilum methyl transferase, tartrate dehy-
dratase β-subunit and nucleoside diphosphate kinase to
be 50%, 95% and 90% soluble respectively [72]. The GFP
reporter system was further used to screen for solubilizing
interaction partners to insoluble targets. Fusion of integra-
tion host factor β upstream to GFP resulted in aggregation,
whereas co-expression of the binding partner (integration
host factor α) increased fluorescence dramatically [73].
A similar approach is the use of selective pressure. By fus-
ing target proteins with chloramphenicol acetyl trans-
ferase (CAT) more soluble fusion protein mutants were
selected on media containing progressively higher levels
of chloramphenicol [74]. Furthermore, selective pressure
(fusion to kanamycin phosphotransferase) was used in a
system aiming at the obtainment of soluble proteins
encoded by cDNA fragments in a high throughput
approach [75].
Another fusion reporter method use the β-galactosidase α
peptide as fusion partner in a screen for lacZα comple-
mentation in a system where inactive lacZΩ is supplied in
trans. Active β-galactosidase can be detected when the α
peptide becomes soluble and restore enzyme activity by
binding to lacZΩ [76].
An innate host cell response is induced when recom-
binantly expressed proteins are misfolded. This response
can be monitored by the transcription from E. coli pro-
moters that are up-regulated when misfolded proteins are
expressed. It was found that the promoter for the small
heat shock protein ibpA could be fused to lacZ and used
as a reporter for misfolded protein [77]. This reporter
could discriminate soluble, partially soluble and insolu-
ble recombinant proteins. Genetic screens and directed
evolution is further reviewed elsewhere [78].
Soluble fusion proteins are not necessarily biologically
active and properly folded. Several reports have demon-
strated that soluble preparations of fusion proteins have
low biological activity as compared to the non-fused pro-
tein [79]. It was shown that a fusion of HPV oncoprotein
E6 to MBP formed soluble multimeric aggregates com-
posed of folded MBP and misfolded E6. These "soluble
inclusion bodies" could be avoided by optimization of
the expression conditions by screening for monodisper-
sity [79].
Alternative strategies
A few strategies that are radically different from the con-
ventional fusion partner and selection approaches have
been developed for the potential rescuing of recombinant
proteins from misfolding in the E. coli cytoplasm.
A system based on artificial oil bodies was developed and
illustrated by a fusion protein composed of oleosin and
GFP [80]. The expressed fusion protein was found in the
insoluble cellular fraction but could be reconstituted as
oil-bodies by addition of triacylglycerol and phospholip-
ids to the purified inclusion bodies. GFP could subse-
quently be separated from the oil bodies using an
engineered factor Xa cleavage site and centrifugation.
An in vivo rescuing system based on the E. coli ribosome
was recently presented [81]. Target proteins are rescued
from in vivo aggregation by fusing them to ribosomal pro-
tein L23. The fusion protein is expressed in a strain of E.
coli deficient in the essential L23 ribosomal protein. This
allows for the covalent coupling of target proteins to the
highly soluble ribosomal particles. Ribosomes with cou-
pled target protein can subsequently be isolated by cen-
trifugation methods and the target protein released in a
highly enriched form by site specific protease cleavage.
Conclusions
We have reviewed the most recent improvements in
obtaining soluble and functional protein preparations
from E. coli recombinants. A subset of the methods focus
on relieving the cellular stress that is a response to the
extreme metabolic situation experienced by the host cell
during the process of hyperexpression of a single or a few
proteins. A second subset of methods focus on improving
the solubility and structural stability of the expressed pro-
tein, by the combination of the target protein with specific
peptide tags. A common trait in modern expression strat-
egies is the skillful combination of the utensils in the
genetic toolbox, but also a constant reconsideration of the
accepted paradigms in trade of protein expression.
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